RNA-Seq Analysis of Clinical Samples from TCGA Reveal Molecular Signatures for Ovarian Cancer

Identifying differentially expressed genes and co-expression modules lead to novel biomarkers. GO, pathway enrichment, network, and tumor stage analysis of 318 ovarian cancer samples from TCGA, categorised into primary and recurrent, pre-menopause and post-menopause, and early and late stage tumors...

Full description

Saved in:
Bibliographic Details
Published inCancer investigation Vol. 41; no. 4; pp. 394 - 404
Main Authors Wadapurkar, Rucha M., Sivaram, Aruna, Vyas, Renu
Format Journal Article
LanguageEnglish
Published England Taylor & Francis 21.04.2023
Subjects
biomarker
Biomarkers
diagnosis
differential expression analysis
Female
Gene Regulatory Networks
Humans
Lithostathine - genetics
Neoplasm Recurrence, Local
Ovarian cancer
Ovarian Neoplasms - genetics
Ovarian Neoplasms - pathology
Sequence Analysis, RNA
TCGA
diagnosis
biomarker
TCGA
differential expression analysis
Ovarian cancer
Online AccessGet full text

Cover

More Information
Summary:Identifying differentially expressed genes and co-expression modules lead to novel biomarkers. GO, pathway enrichment, network, and tumor stage analysis of 318 ovarian cancer samples from TCGA, categorised into primary and recurrent, pre-menopause and post-menopause, and early and late stage tumors was performed. Upregulated and downregulated genes in primary vs recurrent, early stage vs late-stage and pre-menopause vs post-menopause tumors were 84 and 62, 84 and 35, and 88 and 14, respectively. IRAK2 and CXCL8 had higher expression in recurrent tumors while REG1A had higher expression in post-menopause samples. In late stage tumors constant expression of IRAK2 and REG1A was observed, while that of CXCL8 and EGF decreased. These genes may be potential biomarkers for the diagnosis of the disease.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0735-7907
1532-4192
DOI:10.1080/07357907.2023.2182123